Loading...
XSHE002393
Market cap576mUSD
Jan 10, Last price  
16.55CNY
1D
-6.55%
1Q
-1.84%
Jan 2017
-59.93%
IPO
-70.86%
Name

Tianjin Lisheng Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002393 chart
P/E
11.68
P/S
3.67
EPS
1.42
Div Yield, %
1.30%
Shrs. gr., 5y
0.06%
Rev. gr., 5y
-5.17%
Revenues
1.15b
+0.56%
349,443,082393,291,513592,538,348595,702,228737,972,252763,641,6071,117,067,9151,044,397,823773,725,673774,782,192846,853,2231,029,433,4311,503,607,4071,615,276,3731,140,837,5551,091,940,6311,146,589,3841,153,032,801
Net income
362m
+286.54%
100,226,256132,447,588132,007,538154,507,713203,395,229324,769,164297,105,384298,058,98592,883,574114,214,489115,606,305116,817,244184,977,556188,137,4018,615,268122,105,33693,606,639361,827,990
CFO
210m
-36.78%
0174,942,818126,586,709196,142,549186,551,923134,583,458250,722,782289,615,40572,238,880198,128,640173,596,260179,246,598162,686,709268,326,34676,370,096196,336,646331,381,244209,507,394
Dividend
May 28, 20240.84 CNY/sh
Earnings
May 16, 2025

Profile

Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the production and sale of chemical medicines. The company offers tablets, hard capsules, dripping pills, freeze-dried powder injections, water injections, and bulk medicines, as well as intermediates, diagnostic reagents, biochemical reagents, and plastic bottles. It also exports its products. The company is based in Tianjin, China. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd.
URL
https://www.lishengpharma.com/
IPO date
Apr 23, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,153,033
0.56%
1,146,589
5.00%
Cost of revenue
871,237
954,742
Unusual Expense (Income)
NOPBT
281,795
191,847
NOPBT Margin
24.44%
16.73%
Operating Taxes
58,386
24,758
Tax Rate
20.72%
12.90%
NOPAT
223,409
167,090
Net income
361,828
286.54%
93,607
-23.34%
Dividends
(54,736)
(54,736)
Dividend yield
1.14%
1.41%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
28,605
39,710
Long-term debt
7,896
10,739
Deferred revenue
31,828
Other long-term liabilities
42,865
12,440
Net debt
(3,994,322)
(3,123,770)
Cash flow
Cash from operating activities
209,507
331,381
CAPEX
(61,718)
Cash from investing activities
19,361
Cash from financing activities
(48,823)
FCF
256,059
454,584
Balance
Cash
2,220,226
1,993,612
Long term investments
1,810,597
1,180,607
Excess cash
3,973,171
3,116,890
Stockholders' equity
1,578,006
2,639,243
Invested Capital
3,400,841
1,756,956
ROIC
8.66%
9.53%
ROCE
5.44%
4.21%
EV
Common stock shares outstanding
183,669
182,455
Price
26.10
22.59%
21.29
-1.48%
Market cap
4,793,762
23.41%
3,884,467
-1.48%
EV
799,439
760,697
EBITDA
349,100
257,968
EV/EBITDA
2.29
2.95
Interest
876
875
Interest/NOPBT
0.31%
0.46%